MX2018014028A - Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet). - Google Patents

Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).

Info

Publication number
MX2018014028A
MX2018014028A MX2018014028A MX2018014028A MX2018014028A MX 2018014028 A MX2018014028 A MX 2018014028A MX 2018014028 A MX2018014028 A MX 2018014028A MX 2018014028 A MX2018014028 A MX 2018014028A MX 2018014028 A MX2018014028 A MX 2018014028A
Authority
MX
Mexico
Prior art keywords
imaging
immunomodulators
pet
millamolecules
labeled
Prior art date
Application number
MX2018014028A
Other languages
English (en)
Inventor
j donnelly David
M Boy Kenneth
Zhang Yunhui
Kim Joonyoung
Pena Adrienne
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2018014028A publication Critical patent/MX2018014028A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12—Arrangements for detecting or locating foreign bodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a la síntesis y el uso de millamoléculas marcadas con 18F para obtener imágenes de varios procesos dentro del cuerpo, para detectar la localización de moléculas asociadas con patología de la enfermedad, y para monitorear la progresión de la enfermedad.
MX2018014028A 2016-05-19 2017-05-17 Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet). MX2018014028A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (1)

Publication Number Publication Date
MX2018014028A true MX2018014028A (es) 2019-04-04

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014028A MX2018014028A (es) 2016-05-19 2017-05-17 Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).

Country Status (24)

Country Link
US (2) US11103605B2 (es)
EP (2) EP3458111B1 (es)
JP (1) JP6953444B2 (es)
KR (1) KR102378288B1 (es)
CN (1) CN109414514B (es)
AU (1) AU2017268291B2 (es)
BR (1) BR112018073642A2 (es)
CA (1) CA3024844A1 (es)
CY (1) CY1124241T1 (es)
DK (1) DK3458111T3 (es)
EA (1) EA038019B1 (es)
ES (1) ES2864091T3 (es)
HR (1) HRP20210644T8 (es)
HU (1) HUE054306T2 (es)
IL (1) IL262962B (es)
LT (1) LT3458111T (es)
MA (1) MA53402A (es)
MX (1) MX2018014028A (es)
PL (1) PL3458111T3 (es)
PT (1) PT3458111T (es)
RS (1) RS61742B1 (es)
SG (1) SG11201810177VA (es)
SI (1) SI3458111T1 (es)
WO (1) WO2017201111A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
CA3045466A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
CA3048229A1 (en) * 2016-12-23 2018-06-28 The Johns Hopkins University Tumor and immune cell imaging based on pd-l1 expression
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2018237153A1 (en) 2017-06-23 2018-12-27 Bristol-Myers Squibb Company IMMUNOMODULATORS ACTING AS PD-1 ANTAGONISTS
MY197688A (en) 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
US20230183292A1 (en) * 2020-03-16 2023-06-15 Bristol-Myers Squibb Company Immunomodulators

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
CA2253904A1 (en) 1996-05-03 1997-11-13 Immunomedics, Inc. Targeted combination immunotherapy of cancer
DE69738353T2 (de) 1996-07-12 2009-09-24 Immunomedics, Inc. Radiometall-bindende peptide analoge
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
CA2302360C (en) 1997-09-03 2005-11-15 Immunomedics, Inc. Fluorination of proteins and peptides for f-18 positron emission tomography
EP2990411B1 (en) 2007-03-26 2017-05-03 The University of Tokyo Process for synthesizing cyclic peptide compound
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
EP2647720B1 (en) 2010-12-03 2019-06-19 The University of Tokyo Peptide library production method, peptide library, and screening method
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
WO2013010573A1 (en) 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
RU2014143443A (ru) 2012-03-29 2016-05-20 Ориджин Дискавери Текнолоджиз Лимитед Иммуномодулирующие циклические соединения
IN2014KN02752A (es) 2012-06-06 2015-05-08 Polyphor Ag
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
EP4356960A2 (en) 2013-03-15 2024-04-24 F. Hoffmann-La Roche AG Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
PL3041468T3 (pl) 2013-09-06 2018-12-31 Aurigene Discovery Technologies Limited Pierścieniowe związki peptydomimetyczne jako immunomodulatory
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
CN106999536B (zh) 2014-09-11 2020-11-27 百时美施贵宝公司 Pd-1/pd-l1及cd80(b7-1)/pd-l1蛋白质/蛋白质相互作用的大环抑制剂
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
JP6701217B2 (ja) 2014-11-25 2020-05-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 生物学的製剤の１８ｆ−放射性標識方法および組成物
CN114591420A (zh) 2014-11-25 2022-06-07 百时美施贵宝公司 用于成像的新型pd-l1结合多肽
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2018237153A1 (en) 2017-06-23 2018-12-27 Bristol-Myers Squibb Company IMMUNOMODULATORS ACTING AS PD-1 ANTAGONISTS
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators

Also Published As

Publication number Publication date
HUE054306T2 (hu) 2021-08-30
KR20190009330A (ko) 2019-01-28
IL262962B (en) 2020-04-30
HRP20210644T8 (hr) 2021-06-25
JP6953444B2 (ja) 2021-10-27
CN109414514A (zh) 2019-03-01
WO2017201111A1 (en) 2017-11-23
LT3458111T (lt) 2021-05-25
PL3458111T3 (pl) 2021-06-28
CY1124241T1 (el) 2022-07-22
CN109414514B (zh) 2022-03-11
EP3458111B1 (en) 2021-03-03
JP2019520328A (ja) 2019-07-18
EP3458111A1 (en) 2019-03-27
EP3827849A1 (en) 2021-06-02
BR112018073642A2 (pt) 2019-02-26
EA201892635A1 (ru) 2019-04-30
AU2017268291A1 (en) 2019-01-17
SG11201810177VA (en) 2018-12-28
CA3024844A1 (en) 2017-11-23
DK3458111T3 (da) 2021-04-26
AU2017268291B2 (en) 2022-09-29
EA038019B1 (ru) 2021-06-23
RS61742B1 (sr) 2021-05-31
SI3458111T1 (sl) 2021-07-30
KR102378288B1 (ko) 2022-03-23
MA53402A (fr) 2021-06-02
US20190117801A1 (en) 2019-04-25
ES2864091T3 (es) 2021-10-13
HRP20210644T1 (hr) 2021-05-28
PT3458111T (pt) 2021-04-09
US11103605B2 (en) 2021-08-31
IL262962A (en) 2018-12-31
US20210386876A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
MX2018014028A (es) Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).
MX2017006785A (es) Metodos y composiciones para radioetiquetado con 18f de productos biologicos.
HK1251257A1 (zh) 用於醫治疾病的外泌體的用途
MX2021014367A (es) Anticuerpos tau humanizados en enfermedad de alzheimer.
HK1253734A1 (zh) 用作RORγ激動劑和用於治療疾病的芳基二氫-2H-苯並[B][1，4]噁嗪磺酰胺和相關化合物
IL246917A0 (en) Biomarker and early diagnosis methods for Alzheimer's disease
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
IL256685B (en) An isolated tau-binding antibody and its use in the treatment and diagnosis of tauopathy
EP3577455A4 (en) BIOMARKERS FOR THE DIAGNOSIS AND CHARACTERIZATION OF ALZHEIMER'S DISEASE
ZA201804079B (en) Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease
DK3463351T3 (da) Behandling til parkinsons sygdom
BR112017011543A2 (pt) peptídeos cíclicos derivados de cd44v6 para o tratamento de cânceres e doenças relacionadas à angiogênese
IL266778A (en) Combined discrimination for the differential diagnosis of Alzheimer's disease
EP3555319C0 (en) DIAGNOSIS OF PARKINSON'S DISEASE DUE TO REDUCED TOTAL TRANSLATION
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
GB201601544D0 (en) Kidney disease diagnostic
NZ732381A (en) Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide
SG11201703624PA (en) Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers
PL3449009T3 (pl) Biomarkery mikroRNA we krwi do diagnozowania choroby Alzheimera
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
IT201700112846U1 (it) "membrana bugnata di sicurezza per discariche"
GB201616502D0 (en) The use of brain waves as biomarkers for alzheimers disease and combined treatment for early stage diagnosed patients
ES1149283Y (es) Prenda interior para pacientes con algun tipo de enfermedad mental
EA201401218A2 (ru) Способ нозологической экспресс-диагностики
TH1501007171A (th) แอนติ-vegf แอนติบอดีและองค์ประกอบทางเภสัชกรรมสำหรับป้องกัน วินิจฉัย หรือรักษามะเร็ง หรือโรคที่เกี่ยวข้องกับการสร้างหลอดเลือดที่ประกอบด้วยสิ่งเดียวกัน